6th Ace Drug Discovery SummitÂ
18th – 19th Feb 2026
About Us
The 6th Ace Drug Discovery Summit in London, UK, serves as a premier platform bringing together global leaders in pharmaceutical science, biotechnology, and AI. Our mission is to drive innovation and collaboration in drug discovery by showcasing cutting-edge research, transformative technologies, and real-world applications. This summit bridges the gap between academia, industry, and clinical practice, covering themes such as AI-driven drug design, in vitro model evolution, translational research, and next-generation therapeutics. With a curated agenda featuring expert presentations, dynamic panel discussions, and strategic business meetings, we aim to accelerate the development of safe, effective, and personalized treatments. From antibody design using synthetic biology to structure-based drug development and breakthroughs in cell and gene therapy, we spotlight the latest trends and challenges shaping the future of drug website discovery. Join us as we advance scientific excellence and build a community committed to transforming global healthcare.
Why Attend





Solutions at ADDS
The 6th Ace Drug Discovery Summit, London 2026, is a premier gathering of global experts, researchers, and innovators focused on the latest advancements in drug discovery and development. common and
🔷Antibody Engineering
🔷Biochemistry
🔷Bio-informatics
🔷ADMUPI (Toxicology)
🔷Biomarker Validation
🔷Combinatorial Chemistry
🔷Covering Biological studies
🔷Data Management TechnologyÂ
🔷Digital Imaging Technology
🔷Discovery Outsourcing Services
🔷DNA & RNA Analysis
🔷DNA Sequencing Services
🔷 Drug Discovery Technology Platforms
🔷Gene Expression Profiling Solutions
🔷Preclinical
🔷Principal Scientists
🔷Protein identification Services
🔷Research & Development
🔷Transgenesis Services
🔷Genomics
🔷High Throughput Screening
🔷Lead Optimatisation and Profiling, HTS
🔷 Licensing
🔷lmaging/biomarker
🔷Imaging Tools
Who Will Attend
The 6th Ace Drug Discovery Summit, London 2026, is a premier gathering of global experts, researchers, and innovators focused on the latest advancements in drug discovery and development. common and
🔷CEO
🔷CSO
🔷Director Discovery Alliances
🔷Director of Discovery Strategy Portfolio
🔷Director of Screening & Compound Profiling
🔷Executive Director Chemistry
🔷Head of DMPK
🔷Head of Drug Design
🔷Head of Molecular Toxicology
🔷VP Target Discovery & Assessment
🔷Head of R&D Licensing
🔷Head Pharmacology & Toxicology
🔷Principal Scientist
🔷Senior Director Discovery Research
Thought Leaders
Norman Miller
Co-Founder And CSO
| Kutanios Ltd
Â
Asif AhmedÂ
Founder And CEO |
MIRZYME THERAPEUTICS LIMITED
John Maher
CSO |
Leucid Bio
Jamie Cartland
Client Partner | Causaly
Mark Eccleston
CEO | ValiRx
Mikko Turunen
Founder, CSO |
RNatives Inc.
Sanjib Bhakta
Professor of Molecular Microbiology And Biochemistry |
UCL And Birkbeck, University of London
Gergely Toth
CEO & CSO |
Cantabio Pharmaceuticals
Kraiem Merabet Manel
CDO | SKYMAB BIOTHERAPEUTICS
Adele Rowley
Chief Scientific Officer | Mironid
Patrizia Anna d’Alessio
CEO |
 AISA Therapeutics
Maria Carmen Visus Miguel
Senior Director R&D Operations | AOP HEALTH
Philip M Arlen
CEO | Precision Biologics
Shayoni Dutta
Data Science Manager | GSK
Kayleigh Thirlwell
Senior Director | Resolution Therapeutics
Alan PALMER
CEO | Elixa Mediscience
Monica Reis
Group Leader | Resolution Therapeutics
Nahuel Villegas
CSO | Vivan Therapeutics
Duygu Dikicioglu
Associate Professor in Digital Bioprocess Engineering | University of College London
Juan Carlos Mobarec
Head Computational Structural Biology | Astrazeneca
Sara Hegy
Founder Coach and Scientist | GenX Leadership Academy
Stephen Harrison
Founder | Chiton Biosciences
Kathryn Armour
Principal Scientist | LifeArc
SONIAÂ MACIAÂ ESCALANTE
Chief Medical Officer | OneChain Immunotherapeutics
John Spencer
Professor/Director of MedChem, SDDC | Sussex Drug Discovery Centre
Darcie Mulhearn
Target Discovery Team Leader | PhoreMost
Vasiliki E Kalodimou
Director Flow Cytometry-Research and Regenerative Medicine | EUC Frankfurt Branch
Morten Grunnet
Vice President, Head of Neuroscience | Lundbeck
Alejandra Tomas
Professor of Cell Biology |
Imperial College London
Jonathan Mason
Senior Research Advisor, Computational Chemistry |
Centessa Pharmaceuticals
Our Sponsors
Attendee Breakdown
Attendee Demographics
2026 Conference Themes
18 February
Oncolytic Peptides – Turning Cold Tumors Hot
Silico Structure-Based ADMET Prediction in Drug Discovery
AI-driven Drug Design, Screening and Optimization
 Strategies for Predictability Neuroscience Diseases
Bioinformatics and Drug Discovery
The Evolution of in vitro models
Artifical Superintelligent Systems
19 February
Revolutionizing Drug Discovery
NKG2D CAR-T based Immunotherapy of Solid Tumors
Deep Learning for Drug Discovery
Target Discovery and Validation for Emerging Therapeutic
Artificial Intelligence in Drug Discovery and Development
Translational Research in Drug Discovery and Development
Structure-Based Drug Design for Targeting RNA
Our Partners
Venue - The Insurance Hall London, UK
The Insurance Hall London has been the home of the UK Insurance sector for over 80 years. It is a prestigious and impressive event venue steeped in history, heritage and architectural significance, a hidden gem in one of City of London’s most decorated and prestigious buildings.
A Grade II listed building formally opened by His Majesty King George V in 1934, The Insurance Hall offers exceptional and flexible event spaces for conferences, receptions, AGMs, business breakfasts, meetings, lunches and dinners for up to 300 delegates.
